Alzheimer Disease/Dementia

Medicare’s restrictive coverage policies are denying patients with early Alzheimer's disease access to novel treatments. And private payers are following suit.

Updated mRNA COVID-19 vaccines, the first orally disintegrating tablet approved for pregnancy prevention, and 5 more.

Your daily dose of the clinical news you may have missed.

Investigators found as much as a 2-fold difference in being diagnosed with dementia across the US, even after controlling for common individual risk factors.

The AHEAD study program will use plasma biomarker screening, novel PET agents, and other unique approaches to assessing lecanemab effect at the earliest stage of disease.

Your daily dose of the clinical news you may have missed.

The lecanemab Clarity AD open label extension study returned no new safety signals and data reflect the therapy's disease modifying effects on key biomarkers.

A blood test had a diagnostic accuracy of 91% compared with 61% accuracy by primary care clinicians and 73% by dementia specialists, according to new research.

Your daily dose of the clinical news you may have missed.

Donanemab, now 1 of 2 antiamyloid medications available, is unique based on evidence that it can be used in limited duration treatment, based on removal of plaque.

The FDA has assigned a PDUFA action date of January 25, 2025 for the monthly IV maintenance dose.

The AdComm plans to review data from the TRAILBLAZER-ALZ 2 phase 3 clinical trial that served as the foundation for Eli Lilly's original BLA submission to the FDA.

The surprise request for review of the phase 3 TRAILBLAZER-ALZ-2 clinical trial findings will delay the original PDUFA timing beyond first quarter 2024.

The accuracy of the test in detecting Aβ and tau pathology underscores its potential to become an accessible and cost effective tool for Alzheimer diagnosis.

November is Alzheimer Awareness Month and a good time to look at common myths held by clinicians and patients alike - and the facts to refute them.

Findings from phase 3 ACCORD clinical trial demonstrated rapid and sustained clinical response in patients with Alzheimer disease agitation with no new safety signals reported.

At the Clinical Trials on Alzheimer's Disease Meeting, October 24-28, the biotech company will update research on lecanemab, aducanumab, and an early-stage disease treatment.

The Alzheimer's Association chief science officer discusses release of updated diagnostic guidelines for AD, which incorporate use of plasma-based biomarkers.

A majority of older adults agree that all aged ≥65 years should be screened annually for dementia; more than half significantly fear a positive result, the National Poll on Healthy Aging reports.

The highest risk of mortality among a Danish population with dementia occurred within 2 weeks of an opioid prescription but remained significant at 180 days.

Howard Fillit, MD, cofounder/chief scientific officer of the Alzheimer Drug Discovery Foundation, says lecenumab's approval opens the door for future drug development.

FDA's action, based on confirmatory evidence showing slowed disease progression, follows a January 2023 accelerated approval.

Brexpiprazole, an atypical antipsychotic, is the first and only medication approved to treat AD-associated agitation, reported in almost half of people with the disease.

Eli Lilly's investigational drug targeting amyloid plaque slowed clinical decline by 35% in participants with early symptomatic Alzheimer disease at 18 months, the company announced.

Your daily dose of clinical news you may have missed.

Screening for stress among older adults who present to primary care with signs of cognitive impairment could be key to reducing risk and targeting intervention, study authors say.

Your daily dose of clinical news you may have missed.

The large biobank-based study found 22 pairings of a neurodegenerative disorder and a previous viral infection. Vaccines exist against several of those viruses.

Accelerometer-measured physical activity and steps were associated with as much as a 60% lower risk of Alzheimer's disease and related dementias in a new study.

For each cardiometabolic disease, the risk of all-cause dementia rose by 42%; the risk rose 26% for Alzheimer disease and 64% for vascular dementia. Temporal onset and genetics play key roles.